DAFIRO HCT 5 mg/160 mg/25 mg FILM-COATED TABLETS

Introduction

Package Leaflet: Information for the User

Dafiro HCT 5mg/160mg/12.5mg film-coated tablets

Dafiro HCT 10mg/160mg/12.5mg film-coated tablets

Dafiro HCT 5mg/160mg/25mg film-coated tablets

Dafiro HCT 10mg/160mg/25mg film-coated tablets

Dafiro HCT 10mg/320mg/25mg film-coated tablets

amlodipine/valsartan/hydrochlorothiazide

Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.

• Keep this leaflet, you may need to read it again.
• If you have any further questions, ask your doctor or pharmacist.
• This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.

• If you experience any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.

Contents of the pack and other information

1. What is Dafiro HCT and what is it used for
2. What you need to know before you take Dafiro HCT
3. How to take Dafiro HCT
4. Possible side effects
5. Storage of Dafiro HCT
6. Contents of the pack and other information

1. What is Dafiro HCT and what is it used for

Dafiro HCT tablets contain three active substances called amlodipine, valsartan, and hydrochlorothiazide. All these substances help to control high blood pressure.

• Amlodipine belongs to a group of substances called "calcium channel blockers". Amlodipine prevents calcium from entering the blood vessel wall, which prevents the blood vessels from narrowing.
• Valsartan belongs to a group of substances called "angiotensin II receptor antagonists". Angiotensin II is produced by the body and causes the blood vessels to narrow, thereby increasing blood pressure. Valsartan works by blocking the effect of angiotensin II.
• Hydrochlorothiazide belongs to a group of substances known as "thiazide diuretics". Hydrochlorothiazide increases urine production, which also lowers blood pressure.

As a result of the three mechanisms, the blood vessels relax and blood pressure decreases.

Dafiro HCT is used to treat high blood pressure in adult patients whose blood pressure is already controlled while taking amlodipine, valsartan, and hydrochlorothiazide and who can benefit from taking a single tablet containing the three substances.

2. What you need to know before you take Dafiro HCT

Do not take Dafiro HCT

• if you are more than 3 months pregnant. (In any case, it is recommended to avoid taking Dafiro HCT also at the start of your pregnancy - see section Pregnancy).
• if you are allergic to amlodipine or any other calcium channel blocker, valsartan, hydrochlorothiazide, sulfonamide-derived medications (medications used to treat chest or urinary tract infections), or any of the other components of this medication (listed in section 6).

If you think you may be allergic, do not take Dafiro HCT and inform your doctor.

• if you have liver disease, destruction of the small bile ducts within the liver (biliary cirrhosis) that leads to the accumulation of bile in the liver (cholestasis).
• if you have severe kidney problems or if you are undergoing dialysis.
• if you are unable to urinate (anuria).
• if your blood potassium or sodium levels are too low despite treatment to increase potassium or sodium levels in the blood.
• if your blood calcium levels are too high despite treatment to reduce calcium levels in the blood.
• if you have gout (uric acid crystals in the joints).
• if you have severe low blood pressure (hypotension).
• if you have a narrowing of the aortic valve (aortic stenosis) or cardiogenic shock (a situation in which your heart cannot supply enough blood to the body).
• if you have heart failure after a heart attack.
• if you have diabetes or kidney problems and are being treated with a blood pressure-lowering medication that contains aliskiren.

Do not take Dafiro HCT and inform your doctor if any of the above applies to you.

Warnings and precautions

Consult your doctor or pharmacist before starting to take Dafiro HCT

• if you have low potassium or magnesium levels in your blood (with or without symptoms such as muscle weakness, muscle spasms, irregular heartbeat).
• if you have low sodium levels in your blood (with or without symptoms such as fatigue, confusion, muscle contractions, convulsions).
• if you have high calcium levels in your blood (with or without symptoms such as nausea, vomiting, constipation, stomach pain, frequent urination, thirst, muscle contractions, and muscle weakness).
• if you have kidney problems, have undergone a kidney transplant, or have been informed that you have a narrowing of the arteries of the kidney.
• if you have liver problems.
• if you have or have had heart failure or coronary artery disease, in particular if you have been prescribed the maximum dose of Dafiro HCT (10 mg/320 mg/25 mg).
• if you have had a heart attack. Follow your doctor's instructions to carefully start dosing. Your doctor may also check your kidney function.
• if your doctor has informed you that you have a narrowing of the heart valves (so-called "aortic or mitral stenosis") or that the thickness of your heart muscle has increased abnormally (so-called "hypertrophic cardiomyopathy").
• if you suffer from aldosteronism. A disease in which the adrenal glands produce too much aldosterone hormone. In this case, the use of Dafiro HCT is not recommended.
• if you suffer from a disease called systemic lupus erythematosus (also known as "lupus" or "SLE").
• if you have diabetes (high blood sugar levels).
• if you have high cholesterol or triglyceride levels in your blood.
• if you experience skin reactions such as a rash after sun exposure.
• if you have had an allergic reaction to other blood pressure-lowering medications or diuretics, especially if you suffer from asthma and allergies.
• if you have been ill (with vomiting or diarrhea).
• if you have experienced swelling, in particular in the face and throat, while taking other medications (including ACE inhibitors). If you have these symptoms, stop taking Dafiro HCT and contact your doctor immediately. You should never take Dafiro HCT again.
• if you experience abdominal pain, nausea, vomiting, or diarrhea after taking Dafiro HCT. Your doctor will decide whether to continue treatment. Do not stop taking Dafiro HCT on your own.
• if you experience dizziness and/or fainting during treatment with Dafiro HCT, inform your doctor as soon as possible.
• if you experience a decrease in vision or eye pain. These can be symptoms of fluid accumulation in the vascular layer of the eye (choroidal effusion) or an increase in eye pressure and can occur within hours to a week of administration of Dafiro HCT. If left untreated, this can lead to permanent vision impairment.
• if you are taking any of the following medications used to treat high blood pressure:

• an angiotensin-converting enzyme inhibitor (ACE inhibitor) (e.g., enalapril, lisinopril, ramipril), particularly if you have kidney problems related to diabetes.
• aliskiren.

• if you have had skin cancer or if you develop an unexpected skin lesion during treatment. Treatment with hydrochlorothiazide, in particular its long-term use at high doses, may increase the risk of certain types of skin cancer and lip cancer (non-melanoma skin cancer). Protect your skin from sun and UV exposure while taking Dafiro HCT.
• if you have had respiratory or lung problems (such as inflammation or fluid in the lungs) after taking hydrochlorothiazide in the past. If you experience shortness of breath or severe difficulty breathing after taking Dafiro HCT, seek medical attention immediately.

Your doctor may monitor your kidney function, blood pressure, and electrolyte levels (e.g., potassium) in your blood at regular intervals.

See also the information under the heading “Do not take Dafiro HCT”.

Tell your doctor if any of the above applies to you.

Children and adolescents

The use of Dafiro HCT is not recommended in children and adolescents under 18 years of age.

Elderly (65 years and older)

Dafiro HCT can be used in people 65 years and older at the same dose as used in other adults and in the same way as they have already taken the three substances called amlodipine, valsartan, and hydrochlorothiazide. The blood pressure of elderly patients should be monitored periodically, especially those taking the maximum dose of Dafiro HCT (10 mg/320 mg/25 mg).

Other medicines and Dafiro HCT

Tell your doctor or pharmacist if you are using, have recently used, or might use any other medicines. Your doctor may need to change your dose and/or take other precautions. In some cases, you may need to stop taking one of the medicines. This is especially important if you are using any of the following medicines:

Do not take with:

• lithium (a medication used to treat certain types of depression);
• medicines or substances that may increase potassium levels in the blood. These include potassium supplements or salt substitutes that contain potassium, potassium-sparing medications, and heparin;
• an ACE inhibitor or aliskiren (see also the information under the headings “Do not take Dafiro HCT” and “Warnings and precautions”.

Should be used with caution with:

• alcohol, sleeping pills, and anesthetics (medications for patients who are going to undergo surgery and other procedures);
• amantadine (treatment for Parkinson's disease, also used to treat or prevent certain viral diseases);
• anticholinergic medications (medications used to treat various disorders such as gastrointestinal spasms, bladder spasms, asthma, motion sickness, muscle spasms, Parkinson's disease, and as an aid in anesthesia);
• anticonvulsant medications and mood stabilizers used to treat epilepsy and bipolar disorder (e.g., carbamazepine, phenobarbital, phenytoin, fosphenytoin, primidone);
• cholestyramine, colestipol, or other resins (substances used primarily to treat high lipid levels in the blood);
• simvastatin (a medication used to control high cholesterol levels);
• cyclosporine (a medication used in transplants to prevent organ rejection or for other conditions, e.g., rheumatoid arthritis or atopic dermatitis);
• cytotoxic medications (used to treat cancer), such as methotrexate or cyclophosphamide;
• digoxin or other digitalis glycosides (medications used to treat heart problems);
• verapamil, diltiazem (heart medications);
• iodinated contrast media (agents used in imaging studies);
• medications for treating diabetes (oral medications such as metformin or insulins);
• medications for treating gout, such as allopurinol;
• medications that can increase blood sugar levels (beta-blockers, diazoxide);
• medications that can induce "torsades de pointes" (irregular heartbeat), such as antiarrhythmics (medications used to treat heart problems) and some antipsychotics;
• medications that can reduce sodium levels in the blood, such as antidepressants, antipsychotics, antiepileptics;
• medications that can reduce potassium levels in the blood, such as diuretics (medications that increase urine production), corticosteroids, laxatives, amphotericin, or penicillin G;
• medications used to increase blood pressure, such as adrenaline or noradrenaline;
• medications used to treat HIV/AIDS (e.g., ritonavir, indinavir, nelfinavir);
• medications used to treat fungal infections (e.g., ketoconazole, itraconazole);
• medications used to treat inflammation and ulcers of the esophagus (carbenoxolone);
• medications used to relieve pain or inflammation, especially nonsteroidal anti-inflammatory medications (NSAIDs), including selective cyclooxygenase-2 (COX-2) inhibitors;
• muscle relaxants (medications used to relax muscles during surgery);
• nitroglycerin and other nitrates, or other substances called "vasodilators";
• other medications used to treat high blood pressure, including methyldopa;
• rifampicin (used, for example, to treat tuberculosis), erythromycin, clarithromycin (antibiotics);
• St. John's Wort;
• dantrolene (in infusion for severe body temperature abnormalities);
• tacrolimus (used to control the body's immune response, allowing it to accept a transplanted organ);
• vitamin D and calcium salts.

Taking Dafiro HCT with food, drinks, and alcohol

People who have been prescribed Dafiro HCT should not consume grapefruit or grapefruit juice. This is because grapefruit and grapefruit juice can lead to an increase in the levels of the active substance amlodipine in the blood, which can cause an unpredictable increase in the blood pressure-lowering effects of Dafiro HCT. Consult your doctor before drinking alcohol. Alcohol can significantly lower your blood pressure and/or increase the risk of dizziness or fainting.

Pregnancy and breastfeeding

Pregnancy

You must inform your doctorif you are pregnant, think you may be pregnant, or are planning to become pregnant. Your doctor will normally advise you to stop taking Dafiro HCT before you become pregnant or as soon as you find out you are pregnant, and will recommend that you take another blood pressure-lowering medication instead. Dafiro HCT is not recommended during the first trimester of pregnancy and should not be taken after the third month of pregnancy as it may cause serious harm to your baby when administered from that time on.

Breastfeeding

Inform your doctorif you are about to start or are breastfeeding. Amlodipine has been shown to pass into breast milk in small amounts. Dafiro HCT is not recommended for women during breastfeeding. Your doctor may decide to give you a treatment that is more suitable if you want to breastfeed, especially newborns or premature babies.

Consult your doctor or pharmacist before using any medication.

Driving and using machines

As with other medications used to treat high blood pressure, you may feel dizzy, drowsy, nauseous, or have a headache. If you experience these symptoms, do not drive or use tools or machines.

3. How to take Dafiro HCT

Follow the instructions for administration of this medication exactly as indicated by your doctor. If you are unsure, consult your doctor again. This will help you get the best results and reduce the risk of side effects.

The normal dose of Dafiro HCT is one tabletper day.

• It is best to take the tablet at the same time each day. The best time is in the morning.
• Swallow the tablet whole with a glass of water.
• You can take Dafiro HCT with or without food. Do not take Dafiro HCT with grapefruit or grapefruit juice.

Depending on your response to treatment, your doctor may suggest a higher or lower dose.

Do not exceed the prescribed dose.

If you take more Dafiro HCT than you should

If you have accidentally taken too many Dafiro HCT tablets, consult your doctor immediately. You may need medical attention. Excess fluid may accumulate in the lungs (pulmonary edema) causing difficulty breathing that can develop up to 24-48 hours after ingestion.

If you forget to take Dafiro HCT

If you forget to take a dose of this medication, take it as soon as you remember and then take the next dose at the usual time. If it is almost time for the next dose, only take the next tablet at the usual time. Do nottake a double dose (two tablets at the same time) to make up for forgotten doses.

If you stop taking Dafiro HCT

Stopping your treatment with Dafiro HCT may cause your condition to worsen. Do not stop taking the medication unless your doctor tells you to.

Always take this medication, even if you feel well

Hypertensive patients often do not notice any symptoms of their problem. Many feel well. It is very important that you take this medication exactly as your doctor has indicated to obtain the best results and reduce the risk of side effects. Keep your appointments with your doctor even if you feel well.

If you have any further questions on the use of this medication, ask your doctor or pharmacist.

4. Possible Adverse Effects

Like all medicines, this medicine can cause adverse effects, although not all people suffer from them.

As with any combination that contains three active principles, the adverse effects associated with each individual component cannot be excluded. The adverse effects observed with Dafiro HCT or one of its three active principles (amlodipine, valsartan, and hydrochlorothiazide) are listed below and may occur with the use of Dafiro HCT.

Some adverse effects can be serious and require immediate medical attention.

Consult your doctor immediately if after taking this medicine you experience any of the following serious adverse effects:

Frequent(may affect up to 1 in 10patients):

• dizziness
• low blood pressure (feeling of fainting, dizziness, sudden loss of consciousness)

Uncommon(may affect up to 1 in 100patients):

• decreased urine production (reduced kidney function)

Rare(may affect up to 1 in 1,000patients):

• spontaneous bleeding
• irregular heartbeat
• liver disorder

Very Rare(may affect up to 1 in 10,000patients):

• sudden wheezing (sudden wheezing), chest pain, shortness of breath or difficulty breathing
• swelling of the eyelids, face, or lips
• swelling of the tongue and throat that causes great difficulty breathing
• intestinal angioedema: swelling in the intestine that occurs with symptoms such as abdominal pain, nausea, vomiting, and diarrhea
• severe skin reactions that include intense skin rash, hives, redness of the skin all over the body, severe itching, blistering, peeling, and inflammation of the skin, inflammation of the mucous membranes (Stevens-Johnson Syndrome, toxic epidermal necrolysis) or other allergic reactions
• acute difficulty breathing (signs include severe difficulty breathing, fever, weakness, and confusion)
• heart attack
• inflammation of the pancreas that can cause severe abdominal pain and back pain accompanied by a great feeling of discomfort
• weakness, bruising, fever, and frequent infections
• stiffness

Other adverse effects may include:

Very Frequent (may affect more than 1 in 10patients)

• low potassium levels in the blood
• increased lipids in the blood

Frequent (may affect up to 1 in 10patients)

• drowsiness
• palpitations (feeling the heartbeat)
• hot flashes
• swelling of the ankles (edema)
• abdominal pain
• stomach discomfort after eating
• fatigue
• headache
• frequent urination
• high uric acid levels in the blood
• low magnesium levels in the blood
• low sodium levels in the blood
• dizziness, dizziness when standing up
• decreased appetite
• nausea and vomiting
• itchy rash and other types of rash
• inability to achieve or maintain an erection

Uncommon(may affect up to 1 in 100patients)

• rapid heartbeat
• feeling that everything is spinning around
• vision disorder
• stomach discomfort
• chest pain
• increased urea, creatinine, and uric acid in the blood
• high levels of calcium, lipids, or sodium in the blood
• decreased potassium levels in the blood
• bad breath
• diarrhea
• dry mouth
• weight gain
• loss of appetite
• altered sense of taste
• back pain
• swelling of the joints
• cramps/weakness/pain in the muscles
• pain in the limbs
• inability to stand or walk normally
• weakness
• abnormal coordination
• dizziness when standing up or after exercising
• lack of energy
• sleep disturbances

• tingling or numbness
• neuropathy
• sudden and transient loss of consciousness
• low blood pressure when standing up
• cough
• shortness of breath
• throat irritation
• excessive sweating
• itching
• swelling, redness, and pain along a vein
• redness of the skin
• tremors
• mood changes
• anxiety
• depression
• drowsiness
• altered taste
• fainting
• loss of pain sensation
• visual disturbances
• visual impairment
• ringing in the ears
• sneezing/nasal secretion caused by inflammation of the nasal mucosa (rhinitis)
• alteration of bowel habits
• indigestion
• hair loss
• itching of the skin
• discoloration of the skin
• urination disorder
• increased need to urinate at night
• increased frequency of urination
• discomfort or enlargement of the breasts in men
• pain
• feeling of discomfort
• weight loss

Rare(may affect up to 1 in 1,000patients)

• low platelet count in the blood (sometimes with bleeding or bruising under the skin)
• sugar in the urine
• high blood sugar levels
• worsening of diabetic metabolic status
• abdominal discomfort
• constipation
• liver disorders that may present with yellowing of the skin and eyes, or darkening of the urine (hemolytic anemia)
• increased sensitivity of the skin to the sun
• purplish spots on the skin
• kidney disorders
• confusion

Very Rare(may affect up to 1 in 10,000patients)

• decrease in the number of white blood cells in the blood
• decrease in blood platelets that can cause unusual bruising or easy bleeding (red blood cell damage)
• inflammation of the gums
• abdominal swelling (gastritis)
• inflammation of the liver (hepatitis)
• yellowing of the skin (jaundice)
• increase in liver enzymes that may have an effect on some medical tests
• increase in muscle tension
• inflammation of blood vessels often with skin rashes
• sensitivity to light
• disorders combining stiffness, tremors, and/or movement disorders
• fever, sore throat, or mouth ulcers, increased frequency of infections (low or very low white blood cell count)
• pale skin, fatigue, shortness of breath, dark urine (hemolytic anemia, abnormal decrease due to rupture of red blood cells both in blood vessels and in other parts of the body)
• confusion, fatigue, muscle contractions and spasms, rapid breathing (hypochloremic alkalosis)
• severe pain in the upper abdomen (pancreatitis)
• difficulty breathing with fever, cough, wheezing, shortness of breath (respiratory distress, pulmonary edema, pneumonitis)
• facial rash, joint pain, muscle disorder, fever (lupus erythematosus)
• inflammation of blood vessels with symptoms such as rash, red-purple spots, fever (vasculitis)
• severe skin disease that causes skin rash, redness of the skin, blisters on the lips, eyes, or mouth, peeling of the skin, fever (toxic epidermal necrolysis)

Frequency Not Known (frequency cannot be estimated from available data)

• alteration of kidney function test results in blood, increased potassium in the blood, low red blood cell count
• abnormal red blood cell count
• low levels of a certain type of white blood cell and platelets in the blood
• increased creatinine in the blood
• abnormal liver function test
• significant decrease in urine production
• inflammation of blood vessels
• weakness, bruising, and frequent infections (aplastic anemia)
• decreased vision or eye pain due to high eye pressure (possible signs of fluid accumulation in the vascular layer of the eye (choroidal effusion) or acute angle-closure glaucoma)
• shortness of breath
• severe decrease in urine production (possible signs of kidney disorder or kidney failure)
• severe skin disease that causes rash, red skin, blisters on the lips, eyes, or mouth, peeling of the skin, fever (erythema multiforme)
• muscle spasms
• fever (pyrexia)
• blistering skin disease (sign of a disease called bullous dermatitis)
• skin and lip cancer (non-melanoma skin cancer)

Reporting of Adverse Effects

If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is a possible adverse effect that is not listed in this prospectus. You can also report them directly through the national reporting system included in Annex V. By reporting adverse effects, you can contribute to providing more information on the safety of this medicine.

5. Conservation of Dafiro HCT

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiration date that appears on the packaging and blister pack (after CAD/EXP). The expiration date is the last day of the month indicated.

Do not store at a temperature above 30°C.

Keep in the original packaging to protect it from moisture.

Do not use Dafiro HCT if you notice that the packaging is damaged or shows signs of tampering.

Medicines should not be thrown down the drain or into the trash. Ask your pharmacist how to dispose of packaging and medicines that are no longer needed. This will help protect the environment.

6. Packaging Contents and Additional Information

Composition of Dafiro HCT

Dafiro HCT 5mg/160mg/12,5mg film-coated tablets

The active substances of Dafiro HCT are amlodipine (as amlodipine besylate), valsartan, and hydrochlorothiazide. Each film-coated tablet contains 5 mg of amlodipine (as amlodipine besylate), 160 mg of valsartan, and 12.5 mg of hydrochlorothiazide.

The other ingredients are microcrystalline cellulose; crospovidone (type A); anhydrous colloidal silica; magnesium stearate; hypromellose (substitution type 2910 (3 mPa·s)), macrogol 4000, talc, titanium dioxide (E171).

Dafiro HCT 10mg/160mg/12,5mg film-coated tablets

The active substances of Dafiro HCT are amlodipine (as amlodipine besylate), valsartan, and hydrochlorothiazide. Each film-coated tablet contains 10 mg of amlodipine (as amlodipine besylate), 160 mg of valsartan, and 12.5 mg of hydrochlorothiazide.

The other ingredients are microcrystalline cellulose; crospovidone (type A); anhydrous colloidal silica; magnesium stearate; hypromellose (substitution type 2910 (3 mPa·s)), macrogol 4000, talc, titanium dioxide (E171), yellow iron oxide (E172), red iron oxide (E172).

Dafiro HCT 5mg/160mg/25mg film-coated tablets

The active substances of Dafiro HCT are amlodipine (as amlodipine besylate), valsartan, and hydrochlorothiazide. Each film-coated tablet contains 5 mg of amlodipine (as amlodipine besylate), 160 mg of valsartan, and 25 mg of hydrochlorothiazide.

The other ingredients are microcrystalline cellulose; crospovidone (type A); anhydrous colloidal silica, magnesium stearate, hypromellose (substitution type 2910 (3 mPa·s)), macrogol 4000, talc, titanium dioxide (E171), yellow iron oxide (E172).

Dafiro HCT 10mg/160mg/25mg film-coated tablets

The active substances of Dafiro HCT are amlodipine (as amlodipine besylate), valsartan, and hydrochlorothiazide. Each film-coated tablet contains 10 mg of amlodipine (as amlodipine besylate), 160 mg of valsartan, and 25 mg of hydrochlorothiazide.

The other ingredients are microcrystalline cellulose; crospovidone (type A); anhydrous colloidal silica, magnesium stearate, hypromellose (substitution type 2910 (3 mPa·s)), macrogol 4000, talc, yellow iron oxide (E172).

Dafiro HCT 10mg/320mg/25mg film-coated tablets

The active substances of Dafiro HCT are amlodipine (as amlodipine besylate), valsartan, and hydrochlorothiazide. Each film-coated tablet contains 10 mg of amlodipine (as amlodipine besylate), 320 mg of valsartan, and 25 mg of hydrochlorothiazide.

The other ingredients are microcrystalline cellulose; crospovidone (type A); anhydrous colloidal silica, magnesium stearate, hypromellose (substitution type 2910 (3 mPa·s)), macrogol 4000, talc, yellow iron oxide (E172).

Product Appearance and Packaging Contents

The Dafiro HCT 5 mg/160 mg/12.5 mg film-coated tablets are oval, white, with «NVR» on one side and «VCL» on the other side. Approximate size: 15 mm (length) x 5.9 mm (width).

The Dafiro HCT 10 mg/160 mg/12.5 mg film-coated tablets are oval, pale yellow, with «NVR» on one side and «VDL» on the other side. Approximate size: 15 mm (length) x 5.9 mm (width).

The Dafiro HCT 5 mg/160 mg/25 mg film-coated tablets are oval, yellow, with «NVR» on one side and «VEL» on the other side. Approximate size: 15 mm (length) x 5.9 mm (width).

The Dafiro HCT 10 mg/160 mg/25 mg film-coated tablets are oval, brownish-yellow, with «NVR» on one side and «VHL» on the other side. Approximate size: 15 mm (length) x 5.9 mm (width).

The Dafiro HCT 10 mg/320 mg/25 mg film-coated tablets are oval, brownish-yellow, with «NVR» on one side and «VFL» on the other side. Approximate size: 19 mm (length) x 7.5 mm (width).

Dafiro HCT is available in packs containing 14, 28, 30, 56, 90, 98, or 280 film-coated tablets, in multiple packs with 280 film-coated tablets (with 4 boxes, each with 70 film-coated tablets, or 20 boxes, each with 14 film-coated tablets), and in clinical packs with 56, 98, or 280 film-coated tablets in perforated dose blisters. Not all pack sizes may be marketed in your country.

Marketing Authorisation Holder

Novartis Europharm Limited

Vista Building

Elm Park, Merrion Road

Dublin 4

Ireland

Manufacturer

Novartis Farma S.p.A.

Via Provinciale Schito 131

80058 Torre Annunziata (NA)

Italy

Novartis Farmacéutica S.A.

Gran Via de les Corts Catalanes, 764

08013 Barcelona

Spain

Novartis Pharma GmbH

Roonstraße 25

D-90429 Nuremberg

Germany

Novartis Pharma GmbH

Sophie-Germain-Strasse 10

90443 Nürnberg

Germany

For further information, please contact the local representative of the Marketing Authorisation Holder:

Date of Last Revision of this Leaflet:

Other Sources of Information

Detailed information on this medicinal product is available on the European Medicines Agency website http://www.ema.europa.eu